San Francisco, United States
Stämm, founded in 2016 and headquartered in the United States, is making waves in the fields of Biotechnology, Information Technology, and Life Sciences. Known for their slogan, "Inspired by Nature, driven by data, built for humanity," the company is focused on revolutionizing biomanufacturing.
Stämm aims to simplify and enhance the production of biologics and cell therapies by developing accessible, plug-and-play manufacturing solutions. Their approach ensures an automated, continuous, and more efficient process, making scalable, sustainable, and repeatable manufacturing achievable.
Their most recent financial milestone was a Series B investment concluded on April 12, 2023, with significant backing from investors like SOSV and indiebio. Stämm's innovative strides in biotechnology promise a transformative impact on the industry, presenting a compelling opportunity for investors looking to engage with cutting-edge biomanufacturing solutions.
